About Us: Board of Directors

Ronald Lee Krall, MD

Director
Chairman of the Board

{ View Bio }

Dr. Ronald (Ron) Krall is a board-certified neurologist and clinical pharmacologist with significant and varied pharmaceutical experience at the senior executive level. He has worked with Lorex Pharmaceuticals, Abbott Laboratories, ZENECA, AstraZeneca, and GlaxoSmithKline (GSK).

While serving as Chief Medical Officer for GSK, Dr. Krall had leadership responsibility in the Company’s Worldwide Clinical Development, regulatory affairs, drug safety, and medical ethics.  His work includes responsibility for developing several major drugs, including oncology drugs (Ambien, Depakote, Nolvadex, Faslodex, Arimidex, Iressa, Tykerb, Seroquel, and Accolate). He was a lengthy contributing member of the Academy of Medicine’s Forum for Drug Discovery, Development, and Translation.

As a widely respected senior development and policy executive with a very strong experience in product development, he has gained a deep understanding of the importance and utility of actionable diagnostic data to treatment selection.

Dr. Krall received his BA from Swarthmore College and his MD from the University of Pittsburgh.  He currently serves as Adjunct Associate Professor of Neurology at Center for Bioethics and Health Law, University of Pittsburgh, as Collaborator for Observational Health Data Sciences and Informatics Project, and as Pharmaceutical Consultant for SBSky, LLC. He sits on the Board of Directors for Foundation for the National Institutes of Health, BookTrails, and Yampa Valley Community Foundation as Vice-Chairman, Board of Trustees.

Robert E. Henry

Director
Chief Executive Officer

{ View Bio }

Mr. Robert E. Henry is leading another healthcare turnaround success story; his experience in growing, building, and rejuvenating healthcare companies is being applied at Pierian Biosciences, LLC. He has excelled as a Business Development leader, President and Chief Executive Officer and board member with extensive qualifications in operational and financial management, management restructuring, contract negotiations, and international governance. His experience includes extensive board work with both US and international companies, mergers and acquisitions, successfully structuring strong management teams, and raising capital for startups as well as existing companies.

As President and Chief Executive Officer of Pierain Holdings, Inc., the Company has achieved Medicare Laboratory approval, College of American Pathologists approval, Clinical Laboratory Improvement Amendments approval, and state of Tennessee Licensure for the Franklin laboratory. Under his leadership, the Company negotiated agreements with an international cancer treatment center, a Third-Party Administrator, and a large diversified health care company. Mr. Henry is responsible for identifying and obtaining $75 M in private equity funding, as well as leading the acquisition team for a cutting-edge life sciences company.

Mr. Henry’s prior positions have included Senior Vice President-Director Business Development for Symbion Healthcare, President and Chief Executive Officer of American Endoscopy Services, Inc., Chief Operations Officer/Director of Development, Principle with Physicians Alliance, and Development/Marketing with CIRCON ACMI.

Mr. Henry holds an MBA from the Owen Graduate School of Management at Vanderbilt University and a BS, Business Administration-Finance from the University of Tennessee.

Craig Eagle, MD

Director
Chair of Science and Policy Committee
{ View Bio }

Dr. Craig Eagle enjoys a long and successful career in the international pharmaceutical industry with senior executive experience in both large and small biotech companies. He has international experience with multiple health care systems as an oncologist and hematopathologist, clinical trial experience (Phase I-IV) directed at the development and approval of oncology products, and experience as a core member of the leadership team driving the regulatory approvals of new oncology drugs and their associated diagnostics. He has led, or been directly involved with, teams that resulted in eight new products or indications, and the integration of the Pfizer/Wyeth oncology businesses and portfolio

As Vice President of Strategic Alliances and Partnerships for the oncology business unit at Pfizer Inc. and as Director at Generex Biotechnology Corp., Regenicin, Inc., and Assured Pharmacy Inc., Dr. Eagle’s responsibilities have exclusively focused on managing the growth of the companies’ global oncology business through external and internal research, strategic alliances, and M&A oncology acquisitions.

Dr. Eagle’s wealth of oncology experience includes leading and participating in scientific research, regulatory pricing & re-imbursement negotiations for compounds in therapeutic areas, worldwide development of Celecoxib in oncology, global research plans and teams for Irinotecan and Dalteparin, serving as Head of the Oncology Therapeutic Area Global Medical Group for Pfizer, and as a Member of Scientific Advisory Board at Generex Biotechnology Corp.

Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians and the Royal College of Pathologists Australasia.

Judith A. Salerno, MD, MS

Director
Chair of Compensation Committee
Science and Policy Committee

{ View Bio }

Dr. Judith (Judy) Salerno serves as President for The New York Academy of Medicine, and is a board-certified physician in internal medicine with extensive experience in clinical, research, and health policy that spans both government and nonprofit sectors.  In her previous role as President and Chief Executive Officer (CEO) of the Susan G. Komen Breast Cancer Foundation, she was responsible for the day-to-day operation of the organization and for setting Komen’s strategic vision.  Before joining Komen, she was the Leonard D. Schaeffer Executive Officer of the Institute of Medicine of the National Academies and oversaw all programs including the National Cancer Policy Forum, a consortium of government, industry, academic, and consumer representatives that identifies and examines emerging high-priority policy issues in cancer.

Dr. Salerno’s prior positions have included Deputy Director of the National Institute on Aging (NIA) at the National Institutes of Health, U.S. Department of Health and Human Services, Director of the continuum of Geriatrics and Extended Care programs across the nation for the U.S. Department of Veterans Affairs (VA), Washington, D.C., and Associate Chief of Staff at the VA Medical Center in Washington, D.C.  At NIA, she guided the Institute’s research into aging, including studies on Alzheimer’s and other neurodegenerative diseases, frailty and function in late life, and the social, behavioral, and demographic aspects of aging.  While at the VA, she launched widely recognized national initiatives for pain management and improving end-of-life care.

Dr. Salerno earned her M.D. degree from Harvard Medical School in 1985 and a Master of Science degree in Health Policy from the Harvard School of Public Health in 1976.  She also holds a Certificate of Added Qualifications in Geriatric Medicine and was Associate Clinical Professor of Health Care Sciences and of Medicine at the George Washington University until 2001.

Andrew W. Miller, Jr.

Director
Compensation Committee

{ View Bio }

Mr. Andrew (Andy) W. Miller, Jr. is a Managing Partner at Miller Companies and currently serves as chairman of several companies in Health Care Services, Pharmaceutical, Technology, and Diagnostic areas.

Mr. Miller started his career as a private investor in the year 2000. He spent the previous 10 years on Wall Street as an Institutional Broker/Trader focused exclusively on health care services. The group he founded while there became the fifth most profitable division of the investment banking firm Donaldson, Lufkin, and Jenrette, before his exit in 1999.

Over the last seventeen years, Mr. Miller funded and managed his private investment firm which has, in turn, founded and managed over 25 new companies. He serves as chairman of over 10 companies and has created over a billion dollars of value, based on conservative accounting principles.

Mr. Miller’s specific focus has been, and will continue to be, health care solutions. He has also proven himself to be a “turnaround” specialist, having taken potential loss positions and, on average, created over 200% in returns.

Mr. Miller received his BA in Economics from Belmont University and later received an MBA from Vanderbilt’s Owen School of Business Management.

David R. Parkinson, MD

Director
Science and Policy Committee

{ View Bio }

Dr. David Parkinson currently serves as President and Chief Executive Officer for ESSA Pharma, Inc. and has more than twenty years of experience in oncology clinical development, including leading clinical activities with Novartis, Amgen, and Biogen Idec that resulted in global commercialization of the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance®, and Vectibix®.

Dr. Parkinson received his medical degree from the University of Toronto. He completed a Hematology Fellowship at McGill University in Montreal and was a Research Fellow at Tufts University in Boston. He has held academic positions both at the New England Medical Center, Tufts University, and at the MD Anderson, University of Texas.  Dr. Parkinson has authored over 100 peer-reviewed publications and is a recipient of the FDA’s Cody Medal.

Dr. Parkinson currently sits on the Board of Directors for Tocogen, Inc., Essa Pharma Inc., and 3SBio. He maintains various roles in the committees and societies as advisor of the Alfred A. Tubman Medical Research Institute at the University of Michigan and Board Director of the Multiple Myeloma Research Foundation.

Peter Westlake

Director
Compensation Committee

{ View Bio }

Mr. Westlake currently serves as Vice President and Chief Financial Officer of Prometheus Laboratories, Inc.  The Company operates as a subsidiary of Nestlé Health Science S.A. and engages in the development and commercialization of pharmaceutical and diagnostic products.  Before joining Prometheus, Mr. Westlake was Strategy and Acquisitions Finance Manager at Nestlé Health Science S.A., based in Switzerland, and held finance positions in Finance & Control at Nestlé S.A.

Prior to joining Nestlé, Mr. Westlake’s held positions included Director and UK Head of Research at Deutsche Asset Management, Director and Equity Portfolio Manager at Prudential plc., and served as a non-executive director on the UK Accounting Standards Board.

Peter received a BA in Economics from Cambridge University and is a Chartered Accountant and Chartered Financial Analyst.